Vesicular stomatitis virus (VSV) is a widely studied prototype virus that is currently being developed as a vaccine vector and as an oncolytic agent for the treatment of cancer in humans. VSV is a principal example of a virus that suppresses host antiviral responses through the global inhibition of host gene expression. Studies with VSV, which is a highly cytopathic virus, have also contributed fundamental insights into the mechanisms of virus-induced cell death. Both the suppression of host antiviral responses and the induction of cell death depend on the ability of the VSV matrix (M) protein to inhibit host gene expression. The goal of this project is to determine the mechanisms by which M protein suppresses host antiviral responses and the mechanisms by which M protein controls induction of cell death by VSV. VSV inhibits host gene expression at multiple steps, including transcription, translation and nuclear-cytoplasmic RNA transport.
Specific Aim 1 is to determine how M protein suppresses host antiviral responses.
In Aim 1 a, levels of expression of Rae1, one of the cellular targets of M protein, will be altered in cells by siRNA and by overexpression of Rae1, and the effects on M protein-mediated inhibition of host transcription, RNA transport, and translation will be determined.
In Aim 1 b we will determine whether formation of the M protein-Rae1 complex involves post-translational modification of Rae1 and/or formation of a complex with other host cellular factors. These experiments are based on our new data indicating that only a minor population of Rae1 in cells is competent to form a complex with M protein.
In Aim 1 c, the affinity of a panel of M protein mutants for binding to Rae1 will be determined and correlated with the ability of the mutant M proteins to inhibit host transcription, RNA transport, and translation.
Specific Aim 2 is to determine how M protein regulates the induction of apoptosis by VSV.
Aim 2 a will determine the role of upstream signaling molecules in the induction of apoptosis by VSV containing wt or mutant M protein.
In Aim 2 b the relative importance for viral oncolysis in vivo of the apoptotic pathways activated by VSV will be determined by treating tumors established from cells that express inhibitors of apoptosis with wild-type and M protein mutant VSV. These experiments will contribute fundamental new information on the cellular pathways by which viruses suppress antiviral responses through the global inhibition of host gene expression, and how the induction and suppression of antiviral responses leads to death of virus-infected cells. These experiments will establish general principles for viruses that globally inhibit host gene expression, and should also contribute to understanding the basis of tumor destruction by oncolytic viruses.
Genetically modified vesicular stomatitis viruses (VSVs) are currently being developed as vaccines against human diseases and as a potential treatment for human cancers. The goal of this project is to determine how VSV suppresses the antiviral defenses of host cells and how this suppression leads to death of host cells. This will provide fundamental new information on the molecular basis of how viruses like VSV cause disease, and should contribute to development of novel viruses for the treatment of human cancer.
|Westcott, Marlena M; Liu, Jingfang; Rajani, Karishma et al. (2015) Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis. J Virol 89:7944-54|
|Yu, Nanmeng; Puckett, Shelby; Antinozzi, Peter A et al. (2015) Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer. J Virol 89:5250-63|
|Smedberg, Jason R; Westcott, Marlena M; Ahmed, Maryam et al. (2014) Signaling pathways in murine dendritic cells that regulate the response to vesicular stomatitis virus vectors that express flagellin. J Virol 88:777-85|
|Blackham, Aaron U; Northrup, Scott A; Willingham, Mark et al. (2014) Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreaticÂ adenocarcinoma. J Surg Res 187:412-26|
|Blackham, Aaron U; Northrup, Scott A; Willingham, Mark et al. (2013) Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus. Surgery 153:333-43|
|Westcott, Marlena M; Ahmed, Maryam; Smedberg, Jason R et al. (2013) Preservation of dendritic cell function during vesicular stomatitis virus infection reflects both intrinsic and acquired mechanisms of resistance to suppression of host gene expression by viral M protein. J Virol 87:11730-40|
|Stewart 4th, J H; Ahmed, M; Northrup, S A et al. (2011) Vesicular stomatitis virus as a treatment for colorectal cancer. Cancer Gene Ther 18:837-49|
|Gerlier, Denis; Lyles, Douglas S (2011) Interplay between innate immunity and negative-strand RNA viruses: towards a rational model. Microbiol Mol Biol Rev 75:468-90, second page of table of|
|Cary, Zachary D; Willingham, Mark C; Lyles, Douglas S (2011) Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo. J Virol 85:5708-17|
|Ahmed, M; Puckett, S; Lyles, D S (2010) Susceptibility of breast cancer cells to an oncolytic matrix (M) protein mutant of vesicular stomatitis virus. Cancer Gene Ther 17:883-92|
Showing the most recent 10 out of 32 publications